{"id":"W2763263669","doi":"10.1200/jco.2012.30.15_suppl.tps4683","title":"Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Renal cell carcinoma; Discontinuation; Vascular endothelial growth factor; Temsirolimus; Internal medicine; Oncology; Progressive disease; Tyrosine-kinase inhibitor; Platelet-derived growth factor receptor; PI3K/AKT/mTOR pathway; Cancer research; Clinical trial; Cancer; Hepatocellular carcinoma; Chemotherapy; Growth factor; Discovery and development of mTOR inhibitors; Receptor; Signal transduction; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001956329,0.0026568,0.0029168,0.0005429584,0.0005820528,0.001544204,0.001215568,0.001885742,0.006145913],"category_scores_gemma":[0.001421304,0.0008887529,0.001765535,0.0004656352,0.001407886,0.001335562,0.0005004587,0.003787368,0.002131301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001317962,"about_ca_system_score_gemma":0.002048982,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001571028,"about_ca_topic_score_gemma":0.004159685,"domain_scores_codex":[0.9995711,0.000171799,0.00002097754,0.00008587995,0.00003049019,0.0001197415],"domain_scores_gemma":[0.9988195,0.0001887622,0.0001877652,0.00008078724,0.00005419963,0.0006690032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9495223,0.01964489,0.002108645,0.0003348174,0.0005300072,0.0001185198,0.0001041585,0.001204227,0.006074641,0.0001908794,0.002070404,0.0180966],"study_design_scores_gemma":[0.8540039,0.14002,0.003027539,0.00002196432,0.0001561745,0.0001046342,0.00004268323,0.0008949554,0.0006847307,0.0001885006,0.0008377694,0.00001706745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879524,0.00184822,0.0005728644,0.001217485,0.0005782502,0.003439315,0.001881866,0.0001456836,0.002363899],"genre_scores_gemma":[0.9873788,0.001135798,0.001059623,0.001206515,0.0003143271,0.002576426,0.00279285,0.00002894934,0.003506823],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006145913,"threshold_uncertainty_score":0.02056015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06125033449545109,"score_gpt":0.3716325511553506,"score_spread":0.3103822166598995,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}